A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

2011150 citationsJournal Articlebronze Open Access

Authors

Thomas Eigentler · ETH Zurich

Benjamin Weide · Philogen (Italy)

Filippo de Braud · Philogen (Italy)

Gianluca Spitaleri · Philochem (Switzerland)

Antonella Romanini · Philogen (Italy)

Annette Pflugfelder · European Institute of Oncology

Reinerio González‐Iglesias ·

Abstract

The repeated administration of L19-IL2 in combination with dacarbazine is safe and shows encouraging signs of clinical activity in patients with metastatic melanoma. This combination therapy is currently evaluated in a randomized phase II trial with patients with metastatic melanoma.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research Immunotherapy and Immune Responses CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 17, Issue 24, pp. 7732-7742

DOI: 10.1158/1078-0432.ccr-11-1203

Field-Weighted Citation Impact: 14.09